What is the recommended valacyclovir (Valtrex) dosing for initial and recurrent genital herpes and oral herpes, and how should the dose be adjusted in renal impairment?

Valtrex Dosing for Herpes Outbreaks

For recurrent genital herpes outbreaks, start valacyclovir 500 mg twice daily for 3 days at the first sign of prodrome or lesions 1. For initial episodes, use 1 gram twice daily for 10 days 1. For oral herpes (cold sores), take 2 grams twice daily for 1 day (12 hours apart) 1.

Genital Herpes Dosing

Initial Episode

• Valacyclovir 1 gram orally twice daily for 10 days 1
• Most effective when started within 48 hours of symptom onset
• Treatment may be extended if healing incomplete after 10 days

Recurrent Episodes

• Valacyclovir 500 mg orally twice daily for 3 days 1
• Initiate at first sign of prodrome (tingling, itching, burning) or visible lesions
• Early treatment during prodrome or within 1 day of lesion onset provides maximum benefit 2
• Patients should have medication on hand to self-initiate treatment immediately

Suppressive Therapy (for frequent recurrences)

Standard dose: Valacyclovir 1 gram once daily 1

Alternative for ≤9 recurrences/year: Valacyclovir 500 mg once daily 1

• Note: The 500 mg once-daily dose is less effective in patients with ≥10 episodes per year 2

For HIV-infected patients: Valacyclovir 500 mg twice daily 3, 1

• This twice-daily regimen is specifically recommended for immunocompromised patients
• Suppressive therapy reduces recurrences by ≥75% in patients with frequent outbreaks (≥6 per year) 2

Oral Herpes (Cold Sores/Herpes Labialis) Dosing

Valacyclovir 2 grams twice daily for 1 day (doses 12 hours apart) 1

• Must be initiated at earliest symptom (tingling, itching, burning) before lesion development
• Approved for patients ≥12 years old
• Efficacy not established if started after visible lesions appear

Renal Dose Adjustments

Critical consideration: Valacyclovir requires dose adjustment in renal impairment to prevent acute renal failure 1.

Recurrent Genital Herpes Episodes

• CrCl 30-49 mL/min: No reduction needed (500 mg every 12 hours)
• CrCl 10-29 mL/min: 500 mg every 24 hours
• CrCl <10 mL/min: 500 mg every 24 hours

Suppressive Therapy (1 gram daily regimen)

• CrCl 30-49 mL/min: No reduction needed
• CrCl 10-29 mL/min: 500 mg every 24 hours
• CrCl <10 mL/min: 500 mg every 24 hours

Suppressive Therapy (500 mg daily regimen)

• CrCl 30-49 mL/min: No reduction needed
• CrCl 10-29 mL/min: 500 mg every 48 hours
• CrCl <10 mL/min: 500 mg every 48 hours

Cold Sores

• CrCl 30-49 mL/min: 1 gram every 12 hours (do not exceed 1 day)
• CrCl 10-29 mL/min: 1 gram every 24 hours
• CrCl <10 mL/min: 500 mg every 24 hours

Hemodialysis

Administer the recommended dose after hemodialysis 1. Approximately one-third of acyclovir is removed during a 4-hour session.

Special Populations

HIV-Infected Patients

• Episodic therapy: 5-14 days (not 3 days) 3
• Short-course therapy (1-3 days) should NOT be used
• Suppressive therapy: 500 mg twice daily (not once daily) 3
• Monitor for treatment failure after 7-10 days; suspect acyclovir resistance if lesions don't improve

Pregnancy

• Acyclovir is first-choice for HSV in pregnancy due to most extensive safety data 3
• Valacyclovir appears safe but has less pregnancy data than acyclovir 2
• Episodic therapy can be offered; routine suppressive therapy not typically used except in late pregnancy to prevent neonatal transmission

Severe Disease

For disseminated infection, pneumonitis, hepatitis, or CNS complications requiring hospitalization:

• IV acyclovir 5-10 mg/kg every 8 hours for 5-7 days 2
• Switch to oral therapy once lesions begin regressing 3

Key Clinical Pearls

Common pitfalls to avoid:

• Elderly patients and those with underlying renal disease are at increased risk for acute renal failure—always check renal function and adjust doses 1
• Ensure adequate hydration to prevent acyclovir precipitation in renal tubules
• The 500 mg once-daily suppressive dose fails in patients with very frequent recurrences (≥10/year)—use 1 gram daily instead 2
• HIV-infected patients require twice-daily dosing for suppression, not once-daily 3

Treatment timing matters: Maximum benefit occurs when treatment starts during prodrome or within 24 hours of lesion onset 2. Provide patients with a prescription to keep on hand for immediate self-initiation.

Resistance considerations: If lesions don't improve after 7-10 days of therapy, suspect acyclovir resistance (especially in immunocompromised patients) and obtain viral culture with susceptibility testing 3. IV foscarnet is the treatment of choice for resistant HSV.

Suppressive therapy benefits: After 1 year of continuous suppression, reassess need for continuation as recurrence frequency naturally decreases over time in many patients 2. Suppressive therapy reduces but does not eliminate asymptomatic viral shedding or transmission risk.